Cellectar BioSciences

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cellectar BioSciences reports strong Q1 results and eyes FDA submission

Cellectar BioSciences is well-positioned with strong financial backing and promising product developments. Challenges include financial losses, pricing strategy, and market competition. Opportunities lie in upcoming data releases, FDA submission, and global partnerships.

Cellectar BioSciences reports strong Q2 performance and prepares for NDA submission

Cellectar BioSciences showcased strong financial performance and promising trial results in Q2 2024.
While facing challenges in financial restatements and analyst inquiries, the company is progressing well with NDA preparations.
The company's confidence in the NDA filing, supported by robust data, highlights growth opportunities in addressing unmet medical needs.

Cellectar BioSciences excels in Q3 with strong data and growth opportunities

Cellectar BioSciences showcased strong performance in the CLOVER-WaM study and financial stability with a cash position of $34.3 million.
The company's focus on iopofosine I 131's potential in WM treatment and strategic collaborations highlight promising growth opportunities.
However, challenges lie in addressing FDA confirmatory studies, managing funding needs, and balancing research efforts for solid tumors and WM treatment.
Overall, Cellectar's value proposition remains strong, with upcoming product launches and a clear commercialization strategy in place.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:

Cellectar Biosciences to Present at the 36th Annual Roth Conference

FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine I 131 in combination with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant supported investigator-initiated Phase 1 clinical trial.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug.

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI) Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI)

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Tranche A warrants issued as part of the private placement announced in September 2023 have been exercised in full. All participants in the previous financing, led by Rosalind Advisors, exercised their warrants with gross proceeds totaling approximately $44.1 million.

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient

Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225 (225Ac-CLR 121225) an actinium-labeled phospholipid ether (PLE), in pancreatic cancer models.

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.

Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the trial as a potential first-in-class, targeted radiotherapy candidate to treat patients with relapsed/refractory Waldenstrom's macroglobulinemia that have already undergone a minimum of two previous forms of therapy.

Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?

Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.

Cellectar's blood cancer therapy succeeds in trial

FLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitors (BTKi). CLOVER WaM is the largest study to date in relapsed or refractory WM patients post-BTKi therapy and represents the most refractory population ever tested in clinical studies based upon a review of published literature.

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical Conference Call Participants Jonathan Aschoff - ROTH MKM Jeffrey Jones - Oppenheimer Ahu Demir - Ladenburg Jason McCarthy - Maxim Group Operator Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.

Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript

Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that top-line data from the pivotal trial in Waldenstrom's macroglobulinemia (WM) will be released during the JP Morgan Healthcare conference the week of January 8, 2024.

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on its previously announced private placement with certain institutional investors that is expected to result in gross proceeds of up to $102.9 million, including gross proceeds of $24.5 million which the Company received at closing. The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.

News for Cellectar BioSciences Stock (CLRB)